MA
ARQT icon

Montag & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Montag & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$2.65K – 912
2023
Q3 		$2.65K Hold
500
– – ﹤0.01% 839
2023
Q2 		$4.76K Buy
+500
New +$5.55K ﹤0.01% 826

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Montag & Associates's ARQT Position: Q4 2023 in Review

Montag & Associates sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 500 shares — an estimated $2.65K sold.

Montag & Associates first reported a position in ARQT in Q2 2023 and held it in 2 quarters. The position peaked at $4.76K in Q2 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Montag & Associates reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Montag & Associates sold 500 Arcutis Biotherapeutics shares in Q4 2023, an estimated $2.65K.
  • Montag & Associates first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Montag & Associates's Arcutis Biotherapeutics position peaked at $4.76K in Q2 2023.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Montag & Associates's 13F filing for Q4 2023, filed 7 Feb 2024.